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Abstract 
With increasing life expectancy, age-associated cognitive impairment is an 
escalating problem worldwide. Inflammation is one of the features that characterises 
cognitive decline and can stimulate neurodegeneration. Interleukin 6 (IL-6) is a 
cytokine frequently associated with a pro-inflammatory phenotype and increased 
levels have been associated with the pathogenesis of dementia. The rs1800796 
polymorphism in the promoter region of IL-6 gene was previously shown to influence 
IL-6 expression and therefore we hypothesised this gene polymorphism would be 
associated with IL-6 plasma levels and cognitive performance of older adults. 
The present study investigated the association of the rs1800796 polymorphism on 
plasma IL-6 levels and cognition in healthy older adults (n = 207, 74.6 ± 3.4 years, 
51% female) that participated in a Pan-European project (MyoAge). The participants 
were assessed for working memory capacity, executive functioning, episodic 
memory and global cognition using the Cambridge Neuropsychological Test 
Automated Battery CANTAB. Fasting plasma IL-6 levels were measured by ELISA 
and genotyping was performed using the KASP assay.  
Results showed that the rs1800796 polymorphism was in Hardy-Weinberg 
equilibrium (P = 0.16) with the minor allele (C) showing a frequency of 6.3%. There 
were no differences in plasma IL-6 concentrations between the GG-homozygotes 
and C-allele carriers (P = 0.22). The C-allele carriers performed worse on a measure 
of executive functioning (P = 0.035) and had lower global cognitive scores (P = 
0.045), compared to GG-homozygotes. These differences remained significant after 
accounting for age, sex and prior cognitive abilities (P<0.05 for both). There were no 
differences in measures of memory (episodic and working) between the genotypes 
group. 
These findings suggest that the rs1800796 variant may be detrimental for executive 
functioning, but not memory, in healthy older adults.  
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Highlights 
 Inflammation has been linked to cognitive aging and neurodegeneration. 
 207 healthy, older adults were cognitively assessed and IL-6 genotyped 
(rs1800796). 
 Variant carriers performed worse in executive functioning, than non-carriers. 
 IL-6 rs1800796 may confer domain-specific differences in cognitive aging. 
 
1. Introduction 
The number of older adults (≥80 years old) worldwide is projected to triple, from 137 
million in 2017 to 425 million in 2050 (United Nations, 2017). As the world population 
is expected to grow older within the foreseeable future, the issue of age-associated 
diseases is an increasing concern. Age-related cognitive decline differs between 
individuals and the rate of decline can be affected by genetics and lifestyle factors 
such as diet and physical activity levels (Deary et al., 2009). A greater understanding 
of the underlying causes of the normal and pathological cognitive ageing is pivotal 
for the development of effective therapies and personalised approaches.  
 Chronic, systemic inflammation occurs with increasing age (inflammaging) and has 
been implicated in cognitive aging and neurodegeneration (Bettcher and Kramer, 
2014). The inflammaging phenomenon is characterised by an imbalance in 
peripheral cytokine content, such as the upregulation and downregulation of pro- and 
anti-inflammatory cytokines, respectively (Bradburn et al., 2017). One such cytokine 
which has gathered considerable interest over recent years is interleukin-6 (IL-6) 
(see Trapero and Cauli, 2014 for a review). Various ageing cohorts have reported 
negative associations between IL-6 blood levels and performances on cognitive 
measures (Gimeno et al., 2008; Singh-Manoux et al., 2014; Wright et al., 2006). 
These findings are corroborated in a recent meta-analysis on prospective aging 
cohorts, whereby high blood IL-6 levels were associated with a 1.42 time increased 
risk of future cognitive decline, compared to those with low IL-6 levels (Bradburn et 
al., 2018). Further, high IL-6 levels were also associated with a 32% increased risk of 
future dementia in non-demented, older adults (Koyama et al., 2013). 
Given the strong associations with of peripheral protein IL-6 levels with cognitive 
performance in older adults, it is surprising to see little research covering the 
potential genetic contributions to this effect. A recent systematic review by Stacey 
and colleagues (2017) highlighted very few genetic association studies that have 
investigated IL-6 single nucleotide polymorphisms (SNPs) in the context of cognitive 
aging (Stacey et al., 2017), with mixed findings reported (Baune et al., 2008; Dato et 
al., 2010; Krabbe et al., 2009; Marioni et al., 2010; Mooijaart et al., 2013). Of these, 
Baune and colleagues did report a trend for the rs1800796 SNP with motor function 
(Baune et al., 2008). Interestingly, this same SNP has been associated with 
modulating Alzheimer’s disease (AD) risk (Qi et al., 2012). 
 The rs1800796 polymorphism, also referred to as -634G/C or -572G/C, is located 
within the promoter region of the IL-6 gene and has been previously shown to 
contribute to the functional regulation of the expression of the gene (Terry et al., 
2000). Additionally, various cohorts have reported differences in blood IL-6 
concentrations between rs1800796 carriers and non-carriers (Fernandes et al., 
2015; Kitamura et al., 2002). Despite these associations, mainly within pathological 
conditions, little is known concerning healthy aging participants. 
The aims of the present study were to investigate associations of the rs1800796 
polymorphism with plasma IL-6 levels and cognitive performance within a healthy, 
older adult population.  
 
2. Methods 
 
2.1 Participants 
Participants included 207 healthy, non-demented older adults (range: 69 - 80 years 
old) who were recruited to participate in a multinational cross-sectional study called 
MyoAge (McPhee et al., 2013). The study was approved by the ethics committees of 
the respective institutions and all participants provided written informed consent. The 
inclusion, exclusion criteria and study methodology has previously been described in 
detail (McPhee et al., 2013). All measurements were performed according to unified 
standard operating procedures. Participants self-reported education levels (n = 178), 
current smoking status and alcohol intake. Excessive alcohol intake was defined as 
in men >21 units/week and in women >14 units/week. Participants were only 
included if they had a plasma aliquot, DNA sample and cognitive performance data 
available. 
 
2.2 Cognitive functioning 
Participants completed the Geriatric Depression Scale (GDS) (Yesavage et al., 
1982) and Mini–Mental State Examination MMSE (Folstein et al., 1975) prior to 
cognitive assessments to screen for mental wellbeing. The former provides an 
indication of depression, whilst the latter screens for cognitive impairment. Only 
those who had a GDS score of <5 points and MMSE score of >23 points were 
included in the analyses. 
Cognitive assessment was analysed using a touch screen Cambridge Automated 
Neurophysiological Test Automated Battery (CANTAB) device (Cambridge Cognition 
Ltd., UK). Detailed descriptions of the cognitive outputs have been described 
previously (Bradburn et al., 2016). Briefly, participants performed three tasks: Spatial 
Span (working memory capacity), One Touch Stockings of Cambridge (executive 
functioning) and Paired Associate Learning (episodic memory). Scores were 
standardised into Z-scores, based on the average group performance, whereby a 
positive and negative score indicates a higher and lower performance than average, 
respectively. The sum of the three scores was used to represent a global cognition 
score. 
 
2.3 Plasma IL-6 quantification 
Blood samples were previously drawn into EDTA collection tubes from a superficial 
forearm vein from participants in the rested, fasted state during the morning. 
Samples were centrifuged at 2000 x g for 12 minutes and the plasma was aliquoted 
and stored at -80°C until analysis.  
Plasma concentrations of IL-6 were measured using the Quantikine High Sensitivity 
(R&D Systems) enzyme-linked immunosorbent assay (ELISA) kit, as per the 
manufacturer’s instructions. These were all performed in the same laboratory. 
 
2.4 Genotyping 
DNA samples were extracted from peripheral blood samples, as described 
previously (Bradburn et al., 2017), and stored at -80°C until genotyping. Genotyping 
was performed using the Kompetitive Allele Specific PCR (KASP) assay (LGC Ltd). 
A hot start PCR was performed using Eppendorf MasterCycler Gradient Thermal 
Cycler and fluorescence measured using a Stratagene MX3000P qPCR machine 
(Agilent). Fluorescence values were read by the MXPro software and the raw data 
was then interpreted in Microsoft Excel to enable genotype calling. 
 
2.5 Statistical analysis 
Statistical analyses were performed using SPSS statistics (version 25, IBM 
Statistics). Pearson’s Chi-squared goodness of fit test was used to determine if the 
alleles were in the Hardy-Weinberg equilibrium. Data are presented as mean ± 
standard deviation (SD) if normally distributed or median and 25th - 75th percentiles if 
not normally distributed, if otherwise stated. Differences between normally distributed 
(age, height, body mass, BMI) and non-normally distributed (MMSE and GDS 
scores) continuous characteristics between genotype groups were determined using 
independent Student t-tests and Mann-Whitney U tests, respectively. Differences in 
distributions of sex, current smoker status, excessive alcohol use and education 
level between genotype groups was tested using Pearson’s Chi-Squared test. 
Difference in plasma IL-6 concentrations between groups were assessed using the 
Mann-Whitney U test. Difference in cognitive performance between the genotype 
groups was initially determined with independent Student t-tests. Those which were 
significant were further tested to control for covariates using univariate analyses. 
Two models were created: 1) age and sex, 2) age, sex and MMSE score. Since 14% 
of participants failed to report their educational level, we selected MMSE scores to 
account for prior cognitive performance without resulting in loss of power. 
Educational level and MMSE scores correlated significantly (Spearman rank = 0.360, 
P < 0.001), further supporting its use as a proxy for prior cognitive abilities. This 
approach has also been utilised elsewhere (Baune et al., 2008). Residuals in all 
models were normally distributed and homoscedasticity (Levene’s Test) was 
achieved. Significance was accepted at P<0.05. 
 
 
3. Results 
3.1 Genotyping  
In total, 207 older adult participants were genotyped for the rs1800796 SNP. From 
these, 183 were GG-homozygotes, 22 were GC-heterozygotes and 2 were CC-
homozygotes. The minor allele frequency (MAF) was 6.3%, which is similar to the 
MAF in the European division of the 1000Genomes project (5%). The genotype 
frequencies were in Hardy-Weinberg equilibrium (X2 = 1.95, P = 0.16). Since only 
two CC-homozygotes were present, they were grouped with the heterozygotes to 
form a dominant genetic model containing C-allele carriers (CG/CC). 
 
3.2 Cohort characteristics 
Table 1 presents the characteristics of the participants stratified by genotype. 
Overall, no significant differences were observed within the participants for age, sex, 
anthropometric measures, lifestyle habits and prior cognitive wellbeing. 
 
3.3 Differences in plasma IL-6 levels and cognitive performance between 
rs1800796 genotypes 
There were no significant differences for plasma IL-6 concentrations between the 
GG-homozygotes (median: 2.92, 2.17 - 4.09 pg/mL) and C-allele (median: 2.58, 1.95 
- 3.43 pg/mL) carriers (U = 1848, P = 0.22). 
Next, we compared cognitive performance scores between the genotype groups. 
There was no difference for performance on the working memory (GG: 0.004 ± 
1.038, CC/CG: -0.032 ± 0.657; t(205) = -0.169, P = 0.866) and the episodic memory 
(GG: 0.055 ± 0.938, CC/CG: -0.417 ± 1.336; t(26.06) = -1.674, P = 0.106) tasks. On 
the other hand, the GG-homozygotes performed better on the executive functioning 
task (GG: 0.529 ± 1.001, CC/CG: -0.403 ± 0.912; t(205) = -2.119, P = 0.035), as well 
as having a higher global cognitive score (GG: 0.112 ± 2.205, CC/CG: -0.852 ± 
2.193; t(205) = -2.015, P = 0.045), compared to the C-allele carriers. 
Since there were differences for executive functioning and global cognitive scores, 
we next determined the genotype differences after accounting for confounding 
variables. After controlling for participant age and sex (model 1), as well as the 
addition of prior cognitive abilities as measured via MMSE (model 2), the 
significances remained for executive functioning (Figure 1A) and global cognitive 
performance (Figure 1B).  
4. Discussion 
The present study reveals that older adult variant (C allele) carriers of the rs1800796 
polymorphism are associated with lower executive functioning and overall cognitive 
performance, but not memory performance, compared to non-variants (GG-
homozygotes). These differences were independent of participant age, sex and prior 
cognitive abilities. 
 
4.1 The rs1800796 polymorphism and cognitive performance 
The finding that rs1800796 variants perform worse on cognitive tasks, specifically 
executive functioning and overall global scores but not in memory, than non-variants 
is the first finding within an aging cohort. Only one other study has similarly explored 
this variant within the context of cognitive aging (Baune et al., 2008). Specifically, 
Baune and colleagues also failed to report any genetic associations with their 
measures of memory as well as processing speed, but did see a trend for a lower 
motor function performance in the variant carriers. The lack of an association with 
memory performance is also in agreement with neuroimaging analysis of healthy 
adults, whereby there are no links between rs1800796 genotypes and hippocampal 
volumes (Baune et al., 2012), a region integral in memory formations (Bird and 
Burgess, 2008).  
Other investigations have also explored the risk of AD in rs1800796 variants. 
Interestingly, presence of the variant in both additive and dominant models confers a 
lower likelihood (odds ratios 0.66 and 0.73, respectively) of AD diagnosis (Qi et al., 
2012). It is worthwhile noting, however, that the analysis was performed in a 
relatively small number of cohorts (n = 4) and the majority were of East Asian origin. 
 Apart from aging cohorts, there is another report concerning rs1800796 variants and 
cognition. Harding and colleagues, observed variant carriers were more likely to 
have impaired cognitive development in a preliminary study involving prematurely 
born children (Harding et al., 2005). Despite the obvious age difference between the 
aforementioned studies, this study adds further evidence to this variant in modulating 
cognitive functioning. 
Collectively, these studies suggest that rs1800796 is associated with cognitive 
performance and the effects within aging cohorts may be domain-specific, with 
executive functioning, rather than memory, being affected. It will be important for 
future studies to replicate our findings using larger populations with a variety of 
cognitive tasks to elucidate possible domain-specific effects. 
 
4.2 The rs1800796 polymorphism and IL-6 plasma levels 
Interestingly, despite finding associations with cognitive performance, these effects 
seem to be independent of peripheral IL-6 concentrations. The literature concerning 
rs1800796 genotypic associations with peripheral IL-6 levels is mixed. For example, 
some have supported the C allele as producing lower amounts of IL-6 as shown in 
diabetes (Kitamura et al., 2002) and age-related osteoarthritis (Fernandes et al., 
2015). However, there are some reports of an opposite effect with higher circulating 
IL-6 levels among CC-homozygotes, compared to G-allele carriers (Fang et al., 
2017). The lack of group differences reported here is supported by a previous study 
including healthy controls (Bennet et al., 2003). 
One possible explanation for the contradicting reports could be differences in the 
prevalence of inflammatory-related and cardiovascular diseases across the study 
groups. While the present investigation examined the effect of the rs1800796 
polymorphism amongst the healthy old, most of the previous studies included 
individuals suffering with osteoarthritis (Fernandes et al., 2015) or diabetic 
nephropathy (Kitamura et al., 2002). Thus, the polymorphism may have differential 
effects dependent upon the immuno-stimulatory environment. It can be also the case 
that the haplotype, rather than the individual SNP, alters the gene expression. Terry 
et al. (2000) highlighted how the differences in the IL-6 promoter haplotype, including 
rs1800796, influence the level of the IL-6 gene transcription. Finally, it has been 
suggested that the genotypic effects of the IL-6 promoter may be cell-type specific. 
For example, Noss and colleagues found the effects of a different IL-6 polymorphism 
(rs1800795) are apparent in fibroblasts, but not in monocyte or HeLa cell lines (Noss 
et al., 2015). To our knowledge the rs1800796 polymorphism has not been 
functionally characterised within a neuronal cell model.  
Future studies should elaborate on the effect of rs1800796 on IL-6 levels 
longitudinally through ageing, as well as testing these effects within neuronal cell 
lines and following stimulation or immune challenge. These investigations could 
further include haplotype analysis to investigate the individual and combined effects 
of the rs1800796 variant, with relation to IL-6 production.  
  
4.3 Limitations 
The main strength of this study is that the participants were healthy, independent 
older adults, thus free of any clinically neuro-cognitive declines and major 
inflammatory illnesses. While the majority of genetic association studies observe the 
effect of the polymorphism on patients diagnosed with dementia (Qi et al., 2012), this 
study provides an insight into the relationship between rs1800796 in cognitive aging. 
A conceivable weakness of study is the relatively small sample size for a genetic 
association study, which may have reduced the power to detect the associations with 
smaller effects. Further, the design was cross-sectional, therefore cognitive effects 
over time could not investigated. Finally, it is also worth noting that SNPs explain 
only a small variance of higher cognitive function (Davies et al., 2015, 2016), 
therefore other unknown mediators not measured may contribute to cognitive aging. 
 
5. Conclusion 
The results of this study suggest that the IL-6 rs1800796 polymorphism may be 
detrimental in executive functioning, but not memory, performance in healthy, older 
adults. Further, these effects are seemingly independent of IL-6 plasma 
concentrations. Future studies are required to replicate our findings in a larger 
population and to explore the rs1800796 functional effects within a neuronal model. 
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Table 1. Characteristics of the participants stratified by the rs1800796 genotype 
groups. 
Variable 
Genotype 
P Value GG (n=183) GC/CC (n=24) 
Age [years] 74.6 (3.4) 74.3 (3.1) 0.668 
Sex [m/f] 89/94 13/11 0.610 
Height [m] 1.68 (0.09) 1.67 (0.09) 0.776 
Body mass [kg] 71.6 (12.1) 72.4 (13.1) 0.761 
BMI [kg/m2] 25.3 (3.3) 25.7 (3.3) 0.582 
Current Smoker [n (%)] 11 (6) 0 (0) 0.370 
Excessive alcohol use [n 
(%)] 
15 (8) 2 (8) 
1.000 
Education [n (%)]a   0.770 
Basic school 27 (17) 2 (11)  
High school 61 (38) 8 (42)  
University 71 (45) 9 (47)  
MMSE scoreb 29 (28 - 30) 29 (28 - 30) 0.852 
GDS scoreb 1 (0 - 2) 1 (0 - 2) 0.310 
Data presented as mean (SD), unless otherwise stated.  
a Data available in: GG, n = 159 and GC/CC, n = 19. 
b Data presented as median (25th - 75th percentiles). 
 
  
  
Figure 1. Associations between rs1800796 C-allele carriers and GG-homozygotes 
for executive functioning performance (A) and global cognitive score (B). Model 1: 
adjusted for age and sex. Model 2: adjusted for age, sex and MMSE score. Results 
presented are mean ± standard error.  
 
